Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company’s operations are managed on a products basis and include segments that focus on pharmaceutical, animal health, healthcare services, and alliances. In 2019, Merck enhanced its portfolio and pipeline with external innovation and increased investment in new capital projects primarily focused on expanding manufacturing capacity across its key businesses. The company continued to prioritize business development aimed at enhancing its portfolio and strengthening its pipeline by executing several business development transactions. Merck's performance during 2019 demonstrates execution in both commercial and research operations driven by a focus on key growth drivers and innovative pipeline investment. The company is allocating resources to effectively support its commercial opportunities in the near term while making necessary investments to support long-term growth. The company anticipates that actions taken by governments and other third parties to lower healthcare costs will continue to negatively affect revenue performance. Merck's strategic initiatives include enhancing its research and development capabilities, which are designed to increase productivity and improve the probability of success by prioritizing research resources on candidates capable of providing unambiguous advantages to patients and payers. The company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, focusing on collaborations from early research to late-stage compounds. Merck's research and development model is designed to enhance adaptability and resilience in the face of market challenges, ensuring operational continuity and effective resource management. The company’s strong financial profile enables it to fund research and development, support in-line products, and maximize upcoming launches while providing significant cash returns to shareholders. The company has established investment guidelines for its pension and other postretirement plans to create an asset allocation expected to deliver a rate of return sufficient to meet long-term obligations. Merck's restructuring program is focused on optimizing its manufacturing and supply network, which is expected to result in annual net cost savings. The company continuously monitors its legal defense costs and reviews the adequacy of associated reserves, reflecting its commitment to organizational health and resilience. Merck's strategic response to environmental disruptions includes a focus on operational flexibility and the ability to reconfigure its resources in response to unexpected situations. The company’s ongoing efforts in crisis management and preparedness are indicative of its resilience strategies, which are designed to maintain performance under pressure and adapt to complex situations. Through its commitment to innovation and strategic foresight, Merck aims to confront challenges and sustain its competitive advantage in a turbulent market environment.